Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Benatar

Showing results (201-210 of 242) with videos related to

Pageof 25
Sort By:
Nature Communications|October 21, 2022
CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitroKatharina E Meijboom, Abbas Abdallah, Nicholas P Fordham, et al.
Muscle & Nerve|December 22, 2018
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravisKatherine M Clifford, Lisa D Hobson-Webb, Michael Benatar, et al.
JAMA Neurology|February 9, 2026
Long-Term Tofersen in SOD1 Amyotrophic Lateral SclerosisTimothy M Miller, Merit E Cudkowicz, Pamela J Shaw, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 8, 2023
ALSUntangled #70: caffeineJessica Hatch, Paul Barkhaus, Benjamin Barnes, et al.
Translational Neurodegeneration|October 29, 2025
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseasesGang Wu, Wenan Chen, Joanne Wuu, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 8, 2026
ALS untangled #83: clenbuterolAdam Burgess, Olivia Allen, Paul Barkhaus, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 4, 2026
ALSUntangled #82: N-acetylcysteineSandeep Yerraguntla, Bhavya Bakshi, Keshav Chandran, et al.
The Lancet. Neurology|July 26, 2024
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose studyLeonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 26, 2024
ALSUntangled #75: Portable neuromodulation stimulator therapyLaurel Officer, Carmel Armon, Paul Barkhaus, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 6, 2025
Toward therapeutic trials in primary lateral sclerosisErica Scirocco, Matti D Allen, Elisa Giacomelli, et al.
Pageof 25

Showing results (201-210 of 242) with videos related to

Sort By:
Pageof 25
Nature Communications|October 21, 2022
CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitroKatharina E Meijboom, Abbas Abdallah, Nicholas P Fordham, et al.
Muscle & Nerve|December 22, 2018
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravisKatherine M Clifford, Lisa D Hobson-Webb, Michael Benatar, et al.
JAMA Neurology|February 9, 2026
Long-Term Tofersen in SOD1 Amyotrophic Lateral SclerosisTimothy M Miller, Merit E Cudkowicz, Pamela J Shaw, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 8, 2023
ALSUntangled #70: caffeineJessica Hatch, Paul Barkhaus, Benjamin Barnes, et al.
Translational Neurodegeneration|October 29, 2025
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseasesGang Wu, Wenan Chen, Joanne Wuu, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 8, 2026
ALS untangled #83: clenbuterolAdam Burgess, Olivia Allen, Paul Barkhaus, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 4, 2026
ALSUntangled #82: N-acetylcysteineSandeep Yerraguntla, Bhavya Bakshi, Keshav Chandran, et al.
The Lancet. Neurology|July 26, 2024
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose studyLeonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 26, 2024
ALSUntangled #75: Portable neuromodulation stimulator therapyLaurel Officer, Carmel Armon, Paul Barkhaus, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 6, 2025
Toward therapeutic trials in primary lateral sclerosisErica Scirocco, Matti D Allen, Elisa Giacomelli, et al.
Pageof 25